Entasis Therapeutics Holdings Inc. (ETTX)
| Market Cap | 105.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.70M |
| Shares Out | 47.85M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,705 |
| Open | 2.18 |
| Previous Close | 2.20 |
| Day's Range | 2.18 - 2.20 |
| 52-Week Range | 1.40 - 3.88 |
| Beta | 1.44 |
| Analysts | Sell |
| Price Target | 2.04 (-7.3%) |
| Earnings Date | Aug 10, 2022 |
About ETTX
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally adm... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ETTX stock is "Sell." The 12-month stock price forecast is 2.04, which is a decrease of -7.27% from the latest price.
News
The M&A Class Action Firm Continues to Investigate Entasis Therapeutics Holdings Inc. - ETTX
New York, New York--(Newsfile Corp. - June 21, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securit...
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeuti...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.
NEW YORK , May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning th...
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its...
MILWAUKEE , May 24, 2022 /PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Innoviva. Click he...
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates ...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeuti...
ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) to Innoviva, Inc. for $2.20 per share in ...
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Ent...
Innoviva to Acquire Entasis Therapeutics
BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative health...
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conf...
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel anti...
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development o...
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR) Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel an...
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel an...
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Management to host a conference call on November 4, 2021 at 8:00am ET Management to host a conference call on November 4, 2021 at 8:00am ET
Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.
Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate
Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced topline results from its Phase 3 ATTACK trial of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetob...
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacte...
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibac...
Making Money With Penny Stocks During a Stock Market Crash
Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks...
Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of ...